Literature DB >> 6388401

Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial.

A D Blainey, M J Phillips, S Ollier, R J Davies.   

Abstract

Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus was effective in relieving symptoms in selected patients with perennial rhinitis due to this allergen who had responded poorly to topical application of steroids. There was a significant reduction in the nasal response to allergen after six weekly injections only in the actively treated group, but symptomatic improvement greater than that produced by placebo therapy was only evident after a further 10 months of monthly injections. Significantly more placebo-treated patients considered that therapy was ineffective and withdrew from the study. Only one patient developed significant unwanted effects from the injection therapy and had to be withdrawn from the study. We conclude that hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus can be a safe and effective treatment for adults with perennial rhinitis due to this allergen who have responded poorly to nasal corticosteroids, and that those patients who eventually respond clinically are likely to have a diminished nasal response to allergen after the first 6 weeks of therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6388401     DOI: 10.1111/j.1398-9995.1984.tb00873.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

Review 1.  Immunotherapy in allergic respiratory diseases.

Authors:  D Vervloet; X van der Brempt; D Charpin; J Birnbaum
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 2.  Specific immunotherapy in house dust mite allergy.

Authors:  J Bousquet; A Des Roches; L Paradis; H Dhivert; F B Michel
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 3.  Safety considerations in assessing the role of immunotherapy in allergic disorders.

Authors:  J Bousquet; F B Michel
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 4.  Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party.

Authors:  A J Frew
Journal:  BMJ       Date:  1993-10-09

5.  Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).

Authors:  Oliver Pfaar; Claus Bachert; Albrecht Bufe; Roland Buhl; Christof Ebner; Peter Eng; Frank Friedrichs; Thomas Fuchs; Eckard Hamelmann; Doris Hartwig-Bade; Thomas Hering; Isidor Huttegger; Kirsten Jung; Ludger Klimek; Matthias Volkmar Kopp; Hans Merk; Uta Rabe; Joachim Saloga; Peter Schmid-Grendelmeier; Antje Schuster; Nicolaus Schwerk; Helmut Sitter; Ulrich Umpfenbach; Bettina Wedi; Stefan Wöhrl; Margitta Worm; Jörg Kleine-Tebbe; Susanne Kaul; Anja Schwalfenberg
Journal:  Allergo J Int       Date:  2014

Review 6.  Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?

Authors:  Oliver Pfaar; Roy Gerth van Wijk
Journal:  Curr Treat Options Allergy       Date:  2015
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.